Literature DB >> 19896188

Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration.

Ilkka Immonen1, Sanna Seitsonen, Petri Tommila, Tiia Kangas-Kontio, Sakari Kakko, Eeva-Riitta Savolainen, Markku J Savolainen, M Johanna Liinamaa.   

Abstract

PURPOSE: To evaluate the role of vascular endothelial growth factor (VEGF) gene polymorphisms in exudative age-related macular degeneration (AMD).
DESIGN: Retrospective, comparative case series. PARTICIPANTS: Patients with recent exudative AMD (n = 162) and age-matched subjects without AMD (n = 85).
METHODS: Fluorescein angiography (FA), clinical examination, and single nucleotide polymorphism (SNP) genotyping. MAIN OUTCOME MEASURES: The frequencies of 3 VEGF gene SNPs were analyzed, 1 at the promoter site (rs699947, A-->C) and 2 intronic SNPs (rs2146323, A-->C, and rs3025033, A-->G), in relation to the risk of AMD, to choroidal neovascular (CNV) lesion size and configuration, and to the anatomic response to photodynamic therapy (PDT). These SNPs were chosen to cover all the haploblocks of the VEGF gene. The 86 patients who had undergone PDT were classified as either PDT responders or PDT nonresponders based on the outcome of PDT after the last treatment session. For the PDT responders, the treating physician had deemed the lesion to be clinically dry and without leakage from CNV in FA at a visit scheduled at least 12 weeks after the last PDT treatment. For the PDT nonresponders, the PDT sessions had been discontinued by the treating retina specialist because of an apparently poor response and a still exudative lesion after several PDT sessions.
RESULTS: The presence of exudative AMD or lesion size or configuration was not associated with the SNPs studied here. The frequencies of the rs699947 were significantly different in PDT nonresponders and PDT responders. The AA, AC, and CC genotypes were 14%, 39%, and 46%, respectively, in PDT nonresponders, compared with 40%, 48%, and 12%, respectively, in the PDT responders (P = 0.0008). The corresponding frequencies for the rs2146323 AA, AC, and CC genotypes were 4%, 32%, and 64%, respectively, in nonresponders and 24%, 38%, and 38%, respectively, in responders (P = 0.0369). The genotypes of the rs3025033 SNP were distributed evenly between the responders and nonresponders.
CONCLUSIONS: The VEGF gene polymorphic SNPs at rs699947 and rs2146323 are strong determinants of the anatomic outcome after PDT, but the SNPs studied were not associated with the presence of exudative AMD or with the CNV lesion size or configuration. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896188     DOI: 10.1016/j.ophtha.2009.06.037

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

Review 1.  Age-related macular degeneration: genetic and environmental factors of disease.

Authors:  Yuhong Chen; Matthew Bedell; Kang Zhang
Journal:  Mol Interv       Date:  2010-10

2.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Authors:  Stephanie A Hagstrom; Gui-shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; Maureen G Maguire; Daniel F Martin
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

Review 3.  Genetic diversity and medicinal drug response in eye care.

Authors:  Barkur S Shastry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-05       Impact factor: 3.117

4.  Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration in a Turkish population.

Authors:  Yunus Bulgu; Gokhan Ozan Cetin; Vildan Caner; Ebru Nevin Cetin; Volkan Yaylali; Cem Yildirim
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

5.  Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Jane Z Kuo; Tien Y Wong; Frank S Ong
Journal:  Expert Rev Ophthalmol       Date:  2013-04-01

6.  VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration.

Authors:  Isao Nakata; Kenji Yamashiro; Hideo Nakanishi; Akitaka Tsujikawa; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2011-07-09       Impact factor: 2.447

Review 7.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

8.  The Immunogenetic Aspects of Photodynamic Therapy.

Authors:  Chaw-Ning Lee; Tak-Wah Wong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 9.  Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics.

Authors:  Michael B Gorin
Journal:  Mol Aspects Med       Date:  2012-04-27

Review 10.  Mechanism of inflammation in age-related macular degeneration.

Authors:  Francesco Parmeggiani; Mario R Romano; Ciro Costagliola; Francesco Semeraro; Carlo Incorvaia; Sergio D'Angelo; Paolo Perri; Paolo De Palma; Katia De Nadai; Adolfo Sebastiani
Journal:  Mediators Inflamm       Date:  2012-11-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.